Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1674
This examiner grants 61% of resolved cases
Amber Kathleen Faust operates within Tech Center 1600 and Art Unit 1643, where she has managed 71 resolved cases. Her allowance rate stands at 60.6 percent. This rate suggests a moderate level of patentability across her docket, providing a baseline for applicants navigating the biotechnology and organic fields. Practitioners should view this 60.6 percent rate as an indication that success is achievable through diligent prosecution.
A significant feature of her practice is the interview lift of 53.3 percent. This high lift indicates that conducting an examiner interview is a highly effective strategy for overcoming rejections in her art unit. Practitioners should prioritize direct communication to resolve outstanding issues, as the 53.3 percent lift is a highly impactful metric in her profile. Engaging in a dialogue may help clarify technical nuances that written responses alone might not address.
The median days to allowance for her cases is 1353. This timeline reflects the duration from filing to grant for successful applications. With 71 resolved cases, her profile represents a specific subset of examination outcomes. Applicants should prepare for a prosecution cycle that typically spans 1353 days, while leveraging the substantial interview lift to improve their chances within this median timeframe.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18639233 | METHODS FOR TREATING MULTIPLE MYELOMA | Non-Final OA | Janssen Biotech, Inc. |
| 18038101 | ENGINEERED T CELLS FOR EXPRESSION OF CHIMERIC ANITGEN RECEPTORS | Final Rejection | The Regents of the University of California |
| 18138679 | TARGETING STROMA-CANCER INTERACTIONS IN CANCER | Final Rejection | The Regents of the University of California |
| 17310279 | TARGETED DELIVERY OF IFN GAMMA USING ANTIBODY FUSION PROTEINS | Final Rejection | The Regents of the University of California |
| 18249314 | SUSTAINED ANTIBODY AND IMMUNOTHERAPEUTIC DELIVERY TO CERVICAL LYMPH NODES | Non-Final OA | The Johns Hopkins University |
| 17183904 | COMPOSITIONS COMPRISING IL6R ANTIBODIES FOR THE TREATMENT OF UVEITIS AND MACULAR EDEMA AND METHODS OF USING SAME | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18264604 | CHIMERIC ANTIGEN RECEPTOR WITH ENDOGENOUS PROTEIN MOLECULE REPLACING SINGLE DOMAIN ANTIBODY | Final Rejection | ZHEJIANG UNIVERSITY |
| 18703246 | MODULATORS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | Non-Final OA | Flagship Pioneering Innovations VI, LLC |
| 18177023 | TRANSFORMED NATURAL KILLER CELL | Final Rejection | Purdue Research Foundation |
| 18364503 | ENGINEERED NATURAL LIGAND-BASED CAR: DIRECTED EVOLUTION OF THE STRESS-RECEPTOR NKP30 | Non-Final OA | THE TRUSTEES OF DARTMOUTH COLLEGE |
| 17697632 | BISPECIFIC FC MOLECULES | Final Rejection | Amgen Inc. |
| 17430331 | COMBINATION OF T-CELL THERAPY AND TARGETED THERAPY FOR TREATING THERAPY-RESISTANT MELANOMA WITH MUTATIONS IN THE BRAF GENE | Final Rejection | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18570043 | Treatment of Inflammatory Conditions or Diseases | Non-Final OA | Queen Mary University of London |
| 18038423 | COMPOSITIONS AND USES OF PSCA TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS | Final Rejection | City of Hope |
| 18580328 | PHARMACEUTICAL COMPOSITION OF ANTI-ANGPTL3 ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF AND ITS APPLICATION | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 17433817 | SELECTION OF T CELL RECEPTORS | Final Rejection | Gritstone bio, Inc |
| 17431041 | PRODUCING COMPOSITIONS COMPRISING TWO OR MORE ANTIBODIES | Non-Final OA | Merus N.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy